公司本次拟申请注册总额不超过人民币5亿元（含5亿元）的科技创新债，并将根据公司实际资金需求以 及市场环境在注册额度和有效期内择机一次或分次发行，最终注册额度将以中国银行间市场交易商协会 注册通知书中载明的额度为准。 格隆汇2月6日丨福达合金(603045.SH)公布，公司于2026年2月6日召开的第七届董事会第二十二次会议 审议通过了《关于公司拟注册发行科技创新债券的议案》，为积极响应国家科技创新政策导向，加大科 技创新投入力度，同时满足公司经营发展资金需求，进一步拓宽融资渠道，优化债务结构，降低财务费 用，公司拟向中国银行间市场交易商协会申请注册发行科技创新债券。 ...

格隆汇2月6日丨太极集团(600129.SH)公布，为了整合内部资源，优化股权结构：1.公司拟以现金2,108 万元的价格受让全资子公司重庆中药材公司持有的桐君阁中药批发90%股权；2.公司拟以现金235万元 的价格受让间接控股子公司涪陵医药持有的桐君阁中药批发10%股权。转让完成后，公司持有桐君阁中 药批发100%股权，重庆中药材公司和涪陵医药不再持有桐君阁中药批发的股权。 ...

格隆汇2月6日丨皖通高速(600012.SH)公布，为满足区域交通运输发展需求，提升道路通行效率与服务 水平，增强G30连霍高速公路安徽段（下称"连霍高速"）在路网中的竞争能力，促进沿线地区经济社会 高质量发展和本公司健康可持续发展，公司拟投资连霍高速改扩建工程项目。本项目估算总投资金额约 为人民币54.2亿元，其中资本金约为人民币10.84亿元，占总投资的20%，为公司自有资金，其余43.36 亿元由公司通过国内银行贷款等方式解决。 ...

| 市场 | 代码 | 名称 | 示日涨幅 | 景日价格 | 换手率 | 会额 | 净买入 = | | --- | --- | --- | --- | --- | --- | --- | --- | | 旅 | 002812 | 農種股份 | +10.00% | 57.44 | 6.47% | 29.46 Z | 6.10 Z | | 来 | 600759 | 洲际油气 | +10.00% | 5.50 | 20.85% | 44.23亿 | 3.80亿 | | ਸ਼ | 600884 | 杉杉股份 | +10.03% | 14.37 | 9.84% | 25.28亿 | 3.13 Z | | 流 | 002326 | 永太科技 | +10.02% | 28.77 | 12.58% | 28.43 Z | 3.11/Z | | ਸ | 603629 | 利通电子 | +6.60% | 46.01 | 21.75% | 25.23亿 | 2.66 Z | | 流 | 002361 | 神剑股份 8日 | +10.04% | 15.24 | 37.95% | 44.46 Z | 2.39 亿 | | 派 | 00 ...

格隆汇2月6日丨天士力(600535.SH)公布2025年度业绩快报，2025年，公司正式成为华润三九旗下一 员，以创新驱动开启融合发展新篇章，顺利完成与华润三九的"百日融合"并稳步推动"首年融合"各项工 作，在业务稳定、团队稳定、客户稳定基础上，以"四个重塑"为指引，加快与华润三九的资源整合。面 对医药行业集采控费等政策因素影响，公司持续聚焦心血管及代谢、神经/精神、消化三大治疗领域， 积极推进核心业务，全面提升企业效益效率和竞争力，坚持创新驱动，实现高质量发展，向"成为中国 医药市场的领先企业"的目标稳步迈进。报告期内，公司实现营业总收入82.36亿元，同比减少3.08%； 实现归属于上市公司股东的净利润11.05亿元，同比增加15.68%。从变动幅度上看，公司营业收入同比 下降的主要原因是医药商业收入（主要为连锁药店业务）受"门诊统筹"等行业性政策的影响同比减少 14.24%。 ...

格隆汇2月6日丨上海瀚讯(300762.SZ)公布，洞察时空（成都）科技有限公司（简称"洞察时空"或"目标 公司"）系公司参股公司。截至本公告日，洞察时空注册资本为人民币20,000万元。公司持有洞察时空 19.00%股权，自然人卜智勇持有洞察时空25.00%股权，成都时空联觉企业管理咨询合伙企业（有限合 伙）（称"时空联觉"）持有洞察时空21.00%股权，成都聚力时空企业管理咨询合伙企业（有限合伙） （称"聚力时空"）持有洞察时空15.00%股权，嘉兴力鼎深眸股权投资合伙企业（有限合伙）（称"力鼎 深眸"）持有洞察时空10.00%股权，四川天府新区天府之星股权投资基金合伙企业（有限合伙）持有洞 察时空10.00%股权。 基于公司战略发展规划，同时为进一步优化资源配置，公司拟将持有的洞察时空1,200万元注册资本对 应的股权转让给嘉兴力鼎远珩股权投资合伙企业（有限合伙）（简称"力鼎远珩"），转让价格1,200万 元；拟将洞察时空1,300万元注册资本对应的股权转让给嘉兴高岫股权投资合伙企业(有限合伙)（简 称"嘉兴高岫"），转让价格1300万元。同时，洞察时空拟以增资扩股方式进行股权融资，拟由时空联 觉、力鼎 ...

Core Viewpoint - Zhonglai Co., Ltd. (300393.SZ) has announced a commitment to relinquish voting rights for 178 million shares, representing 16.36% of the total share capital, to ensure stable control for Zhejiang Zheneng Electric Power Co., Ltd. [1] Group 1 - The voting rights delegation agreement was signed on November 10, 2022, between Mr. Lin Jianwei, Ms. Zhang Yuzheng, and Zhejiang Zheneng Electric Power Co., Ltd. [1] - The voting rights delegation will last for 36 months from the completion of the share transfer registration, expiring on February 13, 2026 [1]. - Mr. Lin Jianwei has issued a commitment letter on February 6, 2026, to waive his voting rights for the shares after the delegation period ends, with a waiver period of 36 months [1]. Group 2 - The commitment letter specifies conditions under which voting rights may be restored during the waiver period [1]. - The agreement aims to support the sustainable and stable development of the company [1]. - The delegation of voting rights is part of a broader strategy to maintain control stability for Zhejiang Zheneng Electric Power Co., Ltd. [1].

Group 1 - The core point of the article is that Haimeixing (688559.SH) announced a strategic decision to transfer 5% equity of Huachuan Xingguang to Mr. He Changtao, reducing its ownership in Huachuan Xingguang to 75% while still keeping it within the consolidated financial statements of the company [1] - The transaction is described as a prudent decision based on a comprehensive consideration of the company's long-term strategy and the development needs of Huachuan Xingguang [1] - This move is expected to enhance the motivation of the management team and core technical personnel of Huachuan Xingguang [1] Group 2 - The company asserts that the transaction does not harm the interests of the company and all shareholders, particularly minority shareholders [1] - The decision aligns with the company's long-term development strategy [1]

Core Viewpoint - The approval of the listing application for Betahistine Dihydrochloride Tablets by the National Medical Products Administration is a significant milestone for the company, indicating potential growth in the neurology and cerebrovascular disease market [1] Group 1: Product Approval - The company's subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received the acceptance notice for the listing application of Betahistine Dihydrochloride Tablets on February 5, 2026 [1] - Betahistine Dihydrochloride is primarily used for Ménière's disease, vascular headaches, and cerebral arteriosclerosis, and is effective in treating acute ischemic cerebrovascular diseases [1] - The drug is classified as a Category A medication under the national medical insurance and is included in the national essential drug list, addressing the high demand for dizziness-related conditions amid an aging population [1] Group 2: Business Performance - The company is actively expanding its pharmaceutical manufacturing and OEM business, focusing on increasing product variety and quality to enhance market competitiveness [1] - In the first three quarters of 2025, the company's pharmaceutical manufacturing and OEM business achieved sales revenue of 2.3 billion yuan, representing a year-on-year growth of 9.93% [1] - Beijing Jingfeng Pharmaceutical reported a revenue of 431 million yuan in the same period, with a year-on-year increase of 12.48% [1]

格隆汇2月6日丨昆药集团(600422.SH)公布2025年度业绩快报，受前述多重因素影响，公司产品销售规 模及毛利率同比均有所回落，累计实现营业收入预计65.77亿元，较上年同期下降21.72%；实现归母净 利润预计3.5亿元，同比下降46%。公司非经常性损益预计为2.43亿元，同比增加6.1%，主要系参股企业 南京维立志博生物科技股份有限公司港股上市带动公司持有的相关金融资产公允价值变动损益及投资收 益同比显著增长，预计金额为1.19亿元；此外，计入当期损益的政府补助约0.7亿元，同比下降 24.15%。在归母净利润同比下降的情况下，由于非经常性损益同比仍保持增长，导致扣除非经常性损 益后的归母净利润同比降幅相应有所扩大。 ...